Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
Lutio has the potential to offer significant cost savings when available to UK patients.
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)